Abstract 18781: Elevated Trimethylamine-n-oxide Levels May Contributes to Progression of Cerebral Small Vessel Diseases in Poststroke Patients via Blood Brain Barrier Disruption
Introduction: High level of serum gut micro-devrived metabolite trimethylamine-N-oxide(TMAO) have recently been association with cardiovascular disease(CVD) and chronic kidney disease(CKD) risk.
Hypothesis: Here, we aim to test the hypothesis that whether TMAO play a direct contributory role in progression of cerebral small disesase.
Methods: First, we examined the plasma TMAO level in both subjects with and without cerebral small vessel diseases by liquid chromatography with on-line mass spectrometry (LC/MS) analysis. Further, SD rat were raised with either normal chow diet or normal chow diet supplemented with additional high amounts of TMAO. Animals were killed 14 weeks later and brains were preserved. Paraffin-embedded brain sections were stained using hematoxylin and eosin (HE), anti-claudin5 antibody and anti-ZO1 anti body.
Results: It is reveals that TMAO level among cerebral small vessel disease is higher than that in normal control subjects. Results also shown that blood brain barrier was disrupted in high TMAO raised group and expression of tight juction proteins decreased. Sample size should be expanded in our following work. What’s more, cell model of blood brain barrier should be established to demonstrated the molecular mechanism of effect of TMAO.
Conclusions: In conclusion, our study indicates that high serum level of TMAO is association with progression of cerebral small vessel diseases in poststroke patients and raised with diet supplemented with additional high amounts of TMAO lead to blood brain barrier disruption in vivo.
Author Disclosures: Y. Liu: None. Y. Huang: None.
- © 2015 by American Heart Association, Inc.